inotuzumab ozogamicin

Pfizer’s CD22-targeted cancer drug inotuzumab wins an accelerated OK at FDA
Endpoints
Thu, 08/17/17 - 11:52 pm
Pfizer
inotuzumab ozogamicin
acute lymphoblastic leukemia
Pfizer shortens comeback campaign for armed antibody inotuzumab, lands quick FDA review
Endpoints
Tue, 02/21/17 - 11:34 am
Pfizer
inotuzumab ozogamicin
B cell acute lymphoblastic leukemia
priority review
FDA
Following a setback, Pfizer gets a win in Phase III cancer drug study
Fierce Biotech
Tue, 04/21/15 - 09:51 am
Pfizer
clinical trials
CD22-positive non-Hodgkin's lymphoma
inotuzumab ozogamicin